Next Article in Journal
The Potential Role of Cell Penetrating Peptides in the Intracellular Delivery of Proteins for Therapy of Erythroid Related Disorders
Previous Article in Journal
Strategies To Modulate Heritable Epigenetic Defects in Cellular Machinery: Lessons from Nature
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2013, 6(1), 25-31;

Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year

College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia
National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, 11426, Saudi Arabia
Received: 12 November 2012 / Revised: 24 December 2012 / Accepted: 26 December 2012 / Published: 2 January 2013
Full-Text   |   PDF [202 KB, uploaded 2 January 2013]   |  


Recombinant tissue plasminogen activator (rt-PA) is used to restore patency and avoid inadvertent removal of peripheral and central venous catheters. rt-PA was reconstituted (1 mg/mL) then cryopreserved at −30 °C for 1, 2, 3, 6, 8, and 12 months and, then its stability was determined. After cryopreservation for one and two months, rt-PA kept more than 95% of its activity compared to standard samples, while cryopreservation for three months caused 8% loss of activity. However, after cryopreservation for six months or more, rt-PA retained only 87.5% or less activity compared to standard samples. Therefore, it is recommended that reconstituted rt-PA be cryopreserved at −30 °C for a maximum period of three months. View Full-Text
Keywords: cryopreservation; fibrinolysis; stability; tissue plasminogen activator cryopreservation; fibrinolysis; stability; tissue plasminogen activator

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Alkatheri, A. Stability of Recombinant Tissue Plasminogen Activator at −30 °C over One Year. Pharmaceuticals 2013, 6, 25-31.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top